65,000 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Artia Global Partners LP

Artia Global Partners LP bought a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 65,000 shares of the biopharmaceutical company's stock, valued at approximately $3,923,000. Artia Global Partners LP owned approximately 0.07% of Xenon Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at $454,057,000. Bank of New York Mellon Corp raised its holdings in Xenon Pharmaceuticals by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company's stock valued at $23,035,000 after buying an additional 8,980 shares in the last quarter. Siren L.L.C. lifted its position in shares of Xenon Pharmaceuticals by 62.2% in the first quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company's stock worth $76,674,000 after buying an additional 505,803 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Xenon Pharmaceuticals by 13.8% in the fourth quarter. Jennison Associates LLC now owns 1,292,055 shares of the biopharmaceutical company's stock worth $57,910,000 after buying an additional 156,820 shares during the last quarter. Finally, Castleark Management LLC bought a new stake in shares of Xenon Pharmaceuticals during the 1st quarter worth about $3,754,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Xenon Pharmaceuticals Stock Up 5.6%

Shares of XENE stock opened at $63.79 on Thursday. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66. The firm has a market cap of $6.17 billion, a PE ratio of -13.46 and a beta of 0.62. The stock has a 50 day moving average of $62.86 and a 200-day moving average of $56.22.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter last year, the company posted ($1.07) earnings per share. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

Analyst Ratings Changes

XENE has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an "overweight" rating in a report on Wednesday, May 27th. Wells Fargo & Company reaffirmed an "overweight" rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Wall Street Zen upgraded Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, August 1st. Royal Bank Of Canada dropped their price target on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating on the stock in a research report on Friday, August 7th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $77.13.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the firm's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Steven Gannon sold 10,000 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the transaction, the director owned 1,870 shares in the company, valued at approximately $119,792.20. The trade was a 84.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 12,512 shares of company stock valued at $774,088 in the last ninety days. Company insiders own 2.91% of the company's stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source